CVS:NYE-CVS Health Corp (USD)

COMMON STOCK | Healthcare Plans |

Last Closing

USD 64.59

Change

+1.67 (+2.65)%

Market Cap

N/A

Volume

0.02B

Analyst Target

USD 78.78
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap
UNH UnitedHealth Group Incorporate..

-1.55 (-0.26%)

USD 530.79B
ELV Elevance Health Inc

-6.18 (-1.24%)

USD 121.50B
CNC Centene Corp

+0.04 (+0.06%)

USD 38.77B
MOH Molina Healthcare Inc

-0.69 (-0.21%)

USD 19.84B
OSCR Oscar Health Inc

+0.95 (+4.95%)

USD 5.25B
NEUE NeueHealth Inc

-0.08 (-1.52%)

USD 0.05B
CI Cigna Corp

+1.14 (+0.33%)

N/A
HUM Humana Inc

-1.75 (-0.72%)

N/A

ETFs Containing CVS

WBIY WBI Power Factor® High D.. 4.72 % 0.70 %

+0.29 (+-0.54%)

USD 0.06B
UNCU:LSE First Trust US Equity Inc.. 2.97 % 0.00 %

+0.48 (+-0.54%)

USD 0.04B
LUSC:LSE SPDR Barclays 10+ U.S. Co.. 0.43 % 0.00 %

-0.34 (-0.54%)

N/A
LCRP:LSE SPDR Barclays 10+ U.S. Co.. 0.42 % 0.00 %

-0.24 (-0.54%)

USD 0.09B
SUSC:LSE SPDR Barclays 0-3 Year US.. 0.41 % 0.00 %

-0.12 (-0.54%)

N/A
SYBN:F SPDR Barclays 10+ U.S. Co.. 0.37 % 0.00 %

N/A

USD 0.10B
SYBN:XETRA SPDR Barclays 10+ U.S. Co.. 0.37 % 0.00 %

-0.17 (-0.54%)

USD 0.10B
SYBR:F SSgA SPDR ETFs Europe I P.. 0.30 % 0.00 %

N/A

USD 0.23B
SYBR:XETRA SPDR Barclays 3-10 U.S. C.. 0.30 % 0.00 %

-0.01 (-0.54%)

USD 0.23B
IUCB:SW SPDR® Bloomberg 1-10 Yea.. 0.30 % 0.00 %

-0.16 (-0.54%)

USD 0.32B
AGGY WisdomTree Yield Enhanced.. 0.00 % 0.12 %

-0.27 (-0.54%)

USD 0.99B
BSCP Invesco BulletShares 2025.. 0.00 % 0.10 %

-0.01 (-0.54%)

N/A
ESGF 0.00 % 0.40 %

N/A

N/A
ESGL ESGL Holdings Limited Ord.. 0.00 % 0.40 %

-0.03 (-0.54%)

USD 0.08B
IBDL 0.00 % 0.10 %

N/A

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.03 (+-0.54%)

N/A
ILTB iShares Core 10+ Year USD.. 0.00 % 0.06 %

-0.38 (-0.54%)

USD 0.64B
LQD iShares iBoxx $ Investmen.. 0.00 % 0.15 %

-0.61 (-0.54%)

N/A
SPLB SPDR Barclays Long Term C.. 0.00 % 0.08 %

-0.15 (-0.54%)

USD 1.02B
IG Principal Exchange-Traded.. 0.00 % 0.26 %

-0.07 (-0.54%)

USD 0.09B
IGLB iShares 10+ Year Investme.. 0.00 % 0.10 %

-0.35 (-0.54%)

USD 2.86B
IBDT iShares iBonds Dec 2028 T.. 0.00 % 0.10 %

-0.12 (-0.54%)

USD 2.24B
RTH VanEck Retail ETF 0.00 % 0.35 %

+2.68 (+-0.54%)

N/A
RWL Invesco S&P 500 Revenue E.. 0.00 % 0.39 %

+0.98 (+-0.54%)

N/A
SLQD iShares 0-5 Year Investme.. 0.00 % 0.06 %

-0.14 (-0.54%)

USD 2.12B
SPVU Invesco S&P 500® Enhance.. 0.00 % 0.16 %

+0.67 (+-0.54%)

N/A
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.40 %

+0.61 (+-0.54%)

N/A
ICAN 0.00 % 0.50 %

N/A

N/A
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

-7.50 (-0.54%)

USD 0.09B
UINC:LSE First Trust US Equity Inc.. 0.00 % 0.00 %

+34.50 (+-0.54%)

USD 0.31B
VVAL:LSE 0.00 % 0.00 %

N/A

N/A
VGVL:XETRA 0.00 % 0.00 %

N/A

N/A
GBLO 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Healthcare Plans) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.20% 25% F 10% F
Dividend Return 2.53% 100% F 46% F
Total Return -15.67% 25% F 11% F
Trailing 12 Months  
Capital Gain -7.60% 25% F 13% F
Dividend Return 3.72% 100% F 50% F
Total Return -3.88% 25% F 13% F
Trailing 5 Years  
Capital Gain 3.78% 33% F 46% F
Dividend Return 17.86% 100% F 61% D-
Total Return 21.63% 33% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 3.20% N/A N/A 50% F
Dividend Return 5.99% N/A N/A 50% F
Total Return 2.78% N/A N/A 57% F
Risk Return Profile  
Volatility (Standard Deviation) 26.30% N/A N/A 39% F
Risk Adjusted Return 22.76% N/A N/A 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector